LON:SCLP - Scancell Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 5.38 +0.08 (+1.51 %) (As of 04/26/2019 03:40 AM ET)Previous CloseGBX 5.30Today's RangeGBX 5.38 - GBX 5.3852-Week RangeGBX 5 - GBX 15.43Volume200,000 shsAverage Volume536,966 shsMarket Capitalization£20.84 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Scancell Holdings plc engages in the discovery and development of novel monoclonal antibodies and vaccines for the treatment of cancer in the United Kingdom. The company's products include SCIB1, a plasmid DNA vaccine, which is in Phase I/II clinical trials for the treatment of melanoma; SCIB2 to treat lung cancer antigen; and Modi-1, which is in the pre-clinical development to treat triple negative breast cancer, ovarian cancer, and sarcoma. It is also developing Modi-2, a moditope program that is in pre-clinical development to address multiple cancer indications. Scancell Holdings plc has a research collaboration agreement with BioNTech to develop T-cell therapies for the treatment of cancer. It also has a licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA's AMPLIVANT adjuvant technology for the manufacturing, development, and commercialization of Modi-1. The company was incorporated in 2008 and is based in Oxford, the United Kingdom. Receive SCLP News and Ratings via Email Sign-up to receive the latest news and ratings for SCLP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:SCLP Previous Symbol CUSIPN/A CIKN/A Webwww.scancell.co.uk Phone+44-115-8231863Debt Debt-to-Equity RatioN/A Current Ratio19.24 Quick Ratio19.24Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 2.09 per share Price / Cash Flow2.58 Book ValueGBX 3.10 per share Price / Book1.73Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares387,796,992Market Cap£20.84 million Next Earnings DateN/A OptionableNot Optionable Scancell (LON:SCLP) Frequently Asked Questions What is Scancell's stock symbol? Scancell trades on the London Stock Exchange (LON) under the ticker symbol "SCLP." Has Scancell been receiving favorable news coverage? News articles about SCLP stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Scancell earned a news impact score of -1.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. Who are some of Scancell's key competitors? Some companies that are related to Scancell include Botanix Pharmaceuticals (BOT), Antibe Therapeutics (ATE), Orgenesis (ORGS), Bionomics (BNO), Promis Neurosciences (PMN), Tissue Regenix Group (TRX), Protalix Biotherapeutics (PLX), Pediapharm (PDP), IntelGenx Technologies (IGX), Verona Pharma (VRP), Imugene (IMU), OptiBiotix Health (OPTI), Noxopharm (NOX), Actinogen Medical (ACW) and Actinium Pharmaceuticals (ATNM). What other stocks do shareholders of Scancell own? Based on aggregate information from My MarketBeat watchlists, some companies that other Scancell investors own include KAZ Minerals (KAZ), Standard Chartered (STAN), Lloyds Banking Group (LYG), Ascential (ASCL), AorTech International (AOR), Advanced Oncotherapy (AVO), Empyrean Energy (EME), Petropavlovsk (POG), Aminex (AEX) and Sound Energy (SOU). Who are Scancell's key executives? Scancell's management team includes the folowing people: Dr. John Chiplin BPharm, MRPharmS, Ph.D., Exec. Chairman (Age 60)Dr. Clifford Holloway, Chief Exec. OfficerProf. Lindy Gillian Durrant Ph.D., Chief Scientific Officer & DirectorDr. Sally Elizabeth Adams, Devel. Director & Director (Age 58)Mr. Keith Green, Director of Fin. & Admin. How do I buy shares of Scancell? Shares of SCLP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Scancell's stock price today? One share of SCLP stock can currently be purchased for approximately GBX 5.38. How big of a company is Scancell? Scancell has a market capitalization of £20.84 million. What is Scancell's official website? The official website for Scancell is http://www.scancell.co.uk/. How can I contact Scancell? Scancell's mailing address is Department of Clinical Oncology Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The company can be reached via phone at +44-115-8231863. MarketBeat Community Rating for Scancell (LON SCLP)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 172 (Vote Outperform)Underperform Votes: 115 (Vote Underperform)Total Votes: 287MarketBeat's community ratings are surveys of what our community members think about Scancell and other stocks. Vote "Outperform" if you believe SCLP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCLP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/26/2019 by MarketBeat.com StaffFeatured Article: What are the advantages of the Stochastic Momentum Index?